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Background: The addition of tiotropium bromide (TIO) to formoterol fumarate (FOR) improves
exercise performance in patients with chronic obstructive pulmonary disease (COPD). In this
study, we test the hypothesis that the addition of TIO to FOR may improve respiratory muscle
performance and oxygen uptake kinetics after exercise in patients with COPD.
Methods: Thirty eight patients with COPD were randomized to a 2 week treatment with FOR
12 mg twice a day plus TIO 18 mg once a day (FOR þ TIO) or FOR 12 mg twice a day plus placebo
(FOR þ PLA) once a day, using a double-blind crossover design. Inspiratory muscle. Strength
was measured before, immediately after, as well as 2, 5, and 10 min during recovery of
exercise. Time to limit of tolerance on a constant work load exercise test and oxygen uptake
kinetics during recovery were evaluated before and after intervention.
Results: Only FOR þ TIO improved resting (63  10 cm to 84  11 cmH2O) and post-exercise
(49  7 cm to 84  11 cmH2O) maximal inspiratory pressure. Time to limit of tolerance on
the constant work load test was increased by FOR þ PLA and by FOR þ TIO, but the size of
the increment was significantly larger with FOR þ TIO (40.7  7.6% vs. 84.5  8.2%;
p < 0.05). Only FOR þ TIO improved oxygen uptake kinetics during recovery (69  21 to
60  18 s). The improvement in maximal inspiratory pressure (0.78, p < 0.001) and in oxygen
uptake kinetics (0.91, p < 0.001) correlated with the change in time to the limit of tolerance.
Conclusions: The addition of TIO to FOR improves inspiratory muscle strength and oxygen
uptake kinetics after exercise in COPD patients.
ª 2012 Elsevier Ltd. All rights reserved.1 3359 6332.
rgs.br (G.R. Chiappa).
2 Elsevier Ltd. All rights reserved.
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the Institutional Medical Ethics Committee.It has been well established that dynamic hyperinflation is
a key pathophysiological abnormality associated with
effort-induced breathlessnes1 and exercise intolerance in
patients with COPD.2 There is also growing evidence that
skeletal muscle dysfunction is a major factor contributing
to the reduced exercise capacity in COPD patients.3e5 In
particular, respiratory muscle weakness may be associated
with exercise intolerance and with the degree of dyspnea,6
most likely due to early diaphragmatic fatigue. Moreover,
recent data support the view that the rate of decline in
oxygen uptake during early recovery from exercise
correlates well with exercise tolerance in patients with
COPD.3
Previous studies have demonstrated that long-acting-b2
agonists as well as long-acting anticholinergic agents may
improve exercise performance in COPD7e9 and recent
evidence indicates that the anticholinergic agent tio-
tropium bromide (TIO) is superior to the b2-agonist sal-
meterol in improving pulmonary function and preventing
exacerbations.10e12 Moreover, the association of broncho-
dilators of different pharmacological classes may improve
efficacy and reduce the risk of side effects, when
compared to increasing the dose of a single agent.1 We
have previously shown that the addition of TIO to the b2-
agonist formoterol fumarate (FOR) improves effort-
induced dynamic hyperinflation and exercise endurance in
patients with moderate-to-severe COPD,1 but little is
known on the effects of bronchodilators on respiratory
muscle function in this patient population. Indeed, Weiner
et al13 and O’Donnell et al37 showed no effect of salmeterol
administration on inspiratory muscle strength and endur-
ance in patients with COPD. Therefore, the present trial
was conducted to evaluate the effects of the addition of
TIO to FOR on inspiratory muscle function and early
recovery oxygen uptake kinetics in patients with COPD.•Lung function pre/post treatment
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Figure 1 Design of the study. IncCPTX Z incremental
cardiopulmonary test; ctCPX Z constant cardiopulmonary
test; PImax Z inspiratory muscle strength.Methods
Patient population
Patients with stable COPD, who met the criteria defined by
the Global Initiative for Chronic Obstructive Lung Disease
Statement,14 with a long history of smoking (>20 pack-
years) were recruited for the trial. None of the patients
recruited for this study participated in our previous trial.1
Main exclusion criteria were: COPD exacerbation or respi-
ratory infection in the month before recruitment, change in
use of oral or inhaled corticosteroids and xanthine agents in
the month prior to recruitment, diagnosis of current or
previous asthma, allergic rhinitis or other atopic disease
and peripheral eosinophilia> 400/mm3, inability to stop the
usual bronchodilator therapy prior to initial testing, need
for therapy with continuous oxygen, or oxygen saturation
<89% at rest, and contraindication for performing a clinical
exercise test. Patients who previously used TIO or FOR were
not recruited for the study and patients who presented
exacerbations during the development of the protocol were
withdrawn from the final analysis. All subjects gavewritten, informed consent (UNESC 79/2010) as approved byStudy design
A prospective double-blind, randomized, placebo-
controlled, and crossover trial was conducted to compare
the use of FOR plus Placebo (FOR þ PLA) and FOR plus TIO
(FOR þ TIO). The design of the study was the same to that
of our previous trial (Fig. 1).1 In short, after the screening
visit the patients entered a run-in period in which they
discontinued all long-acting bronchodilators and cortico-
steroids. If necessary patients could use a short-acting
bronchodilator (salbutamol 120 mg/ipratropium 20 mg,
Combivent, Boehringer Ingelheim GmbH, Ingelheim,
Germany). Patients were then assigned to a 2 week treat-
ment period with FOR dry powder capsules 12 mg BID
(Fluir, Mantecorp Plc, Rio de Janeiro, Brazil) plus PLA QD
via Handihaler (Boehringer Ingelheim GmbH, Ingelheim,
Germany) or the same FOR regimen plus TIO dry powder
capsules 18 mg QD via Handihaler (Spiriva, Boehringer
Ingelheim GmbH, Ingelheim, Germany). After a 2 week
treatment period, patients discontinued all long-acting BD
for 7 days and crossed-over for a second 2 week-period on
the alternative regimen.1
Throughout this protocol, 5 visits were performed. In the
first visit, patients underwent clinical evaluation, pulmo-
nary function testing, blood gas analysis, and a symptom-
limited incremental cardiopulmonary exercise test on their
current medical regimen. A run-in period of 7 days was
allowed for discontinuation of anticholinergic and
b-adrenergic bronchodilators and patients were random-
ized to receive FOR þ PLA or FOR þ TIO for a period of 2
weeks. A 7 day period of washout was allowed and patients
were crossed over to receive the alternative treatment
regimen for a second 2 week period. Before (visits 2 and 4)
and after (visits 3 and 5) the first and the second 2 week
intervention period, pulmonary function, and inspiratory
strength, as well as a constant work rate test (CWT) to the
limit of tolerance (Tlim) were obtained.
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Pulmonary function tests and arterial blood gases
Standard pulmonary function tests, including spirometry
and diffusing capacity of the lung for CO (DLCO) were
performed as previously described,1 using the Vital-
ograph spirometer (Hand-Held 2021 instrument, Ennis,
Ireland) and expressed as percentage of predicted for the
adult Brazilian population.15,16 At visit 1, pulmonary
function tests were performed before and 20 min after
inhalation of salbutamol 400 mg, via metered-dose inhaler.
At visits 2 and 4, pulmonary function tests were performed
without the administration of long- or short-acting bron-
chodilators. At visits 3 and 5, pulmonary function tests
were performed before (trough effect) and 2 h after (peak
effect) the administration of study medications.1,15e17
Arterial partial pressures for O2 and CO2 were obtained
during visit 1 from samples taken by radial artery punc-
ture, and analyzed in the ABL 330 system (Radiometer,
Copenhagen, Denmark).
Inspiratory muscle strength
Maximal inspiratory pressure (PImax) was measured at visits
2 and 4 without the administration of long- or short-acting
bronchodilators and at trough on visits 3 and 5. PImax was
measured using a pressure transducer (MVD-500 V.1.1
Microhard System, Globalmed, Porto Alegre, Brazil), as
previously described.18 The baseline PImax measurements
were repeated at least 12 times to find the mean 6
measurements with less than 10% of variation.19 PImax was
also measured once immediately after Tlim, and on the
2nd, 5th and 10th minute after the CWT.
Exercise tests
All exercise tests were performed on an electronically
braked cycle ergometer (Inbrasport, Porto Alegre, Brazil)
at 60 rpm. Standard metabolic and ventilatory responses
were measured breath-by-breath using a calibrated,
computer-based system (K4b,2 Cosmed, Rome, Italy).
Arterial oxyhemoglobin saturation (SpO2) was determined
by pulse oximetry (POX 010e340, Mediaid, Torrance, USA).
The incremental exercise test started with 2 min unloaded
cycling and increments of 5e10 W per min were added
until exhaustion. Gas exchange variables were averaged
every 5 s, and peak oxygen uptake ( _VO2peak) was defined as
the highest value achieved during the test. Peak gas
exchange values are expressed as percentage of predicted
for the Brazilian population.20 _VO2 at the first ventilatory
threshold was estimated by the V-slope method as previ-
ously described.17 Heart rate (HR) was determined using
the ReR intervals from a 12-lead electrocardiogram.
Subjects were also asked to rate their ‘shortness of breath’
at exercise cessation using the 0e10 Borg’s category-ratio
scale.21
The CWT to Tlim was performed at visits 2 and 4 without
the administration of long- or short-acting bronchodilators
and at trough effect on visits 3 and 5. The constant power
output was chosen to elicit an _VO2that exceeded the firstventilatory threshold by a value of 60% of the difference
between _VO2peak and ventilatory threshold _VO2 (w80%
peak work rate).22 Tlim was defined as the point in time
when patients signaled to stop exercising or could not
maintain the required pedaling rate for 10 s, despite being
encouraged by the investigators. Serial inspiratory
capacity (IC) maneuvers were performed every 2 min
during the test. Assuming that total lung capacity (TLC)
remains constant during exercise, IC maneuvers provide an
estimate of end-expiratory lung volume (EELV Z TLC e
IC).2,23e25
Off-transient _VO2 kinetics
Breath-by-breath _VO2 data during recovery of from CWT
were interpolated second-by-second (SigmaPlot 11.0,
Systat Software, San Jose, CA) and oxygen uptake kinetics
during recovery were calculated as previously
described.22,26 In short, the time constant of the decay in
_VO2 during recovery from CWE (t _VO2off) was determined by
fitting an exponential curve, using the value at the end of
exercise as baseline. The equation applied27,28 was:
_VO2ðtÞZ _VO2 baseþD _VO2

et=t  1
Where _VO2ðtÞ is the _VO2 at time t, _VO2 base is the _VO2 at
the end of exercise, D _VO2 is the amplitude of the response
during recovery, and t is the time constant. The time
constant was derived by nonlinear regression using least-
squares and iterative techniques.
Statistical analysis
Considering the 2  2 crossover design, a sample size of 30
patients was estimated to detect a between-treatment
difference in post-exercise PImax of 25% with b and
a errors set at 15% and 5%, respectively. Data are reported
as mean  SD or median (range). Repeated measures
analysis of variance (ANOVA) was used to test for signifi-
cant differences at different visits and time points,
according to each treatment. Non-paired or paired t-tests
were used as appropriate. Pearson’s product moment
correlation was used to assess the level of association
between continuous variables. Differences were declared
significant if p < 0.05.
Results
Fig. 1 shows the design of the study. Forty nine patients
were assessed for eligibility. Five patients did not meet
inclusion criteria and 3 refused to participate. Therefore,
41 patients were randomized. Twenty one patients were
randomized to first receive FOR þ TIO, but 1 patient had an
exacerbation during the first intervention period and
another patient had an exacerbation during the washout
period. Twenty patients were randomized to first receive
FOR þ PLA, but 1 patient had an exacerbation during the
first intervention period. Therefore, 19 patients in each
group crossed to the second part of the trial and all
completed the study.
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capacity
As shown in Table 1, patients with COPD had moderate-to-
severe airflow obstruction with increased static lung
volumes and reductions in DLCO. They had mild reduction in
resting PaO2 and SaO2, but normal PaCO2. Exercise toler-
ance was markedly reduced, most likely due to pulmonary-
ventilatory limitation, as suggested by increased VE peak/
MVV. Breathlessness and leg effort were similarly described
as the exercise-limiting symptoms.
Pulmonary function
Table 2 shows the results of pulmonary function test before
and after 2 weeks of treatment, including effects at trough
(before medication) and at peak (2 h after medication).Table 1 Baseline characteristics.
Values
Age, years 56  7
Body Mass Index, kg m2 25  3
Pulmonary Function
FEV1, L (%predicted) 1.21  0.33 (44  9)
FVC, L (%predicted) 2.66  0.48 (42  8)
FEV1/FVC 0.45  0.14
IC, L (%predicted) 2.02  0.34 (78  18)
TLC, L (%predicted) 6.02  0.99 (108  12)
RV, L (%predicted) 3.01  0.43 (168  48)
DLCO, (% predicted) 55  14
Arterial blood gases
PaO2, mmHg 69  8
SaO2, % 92  2
PaCO2, mmHg 39.5  4.5
Cardiopulmonary exercise testing
_VO2 peak, ml min
-1 988  183
_VO2 peak, % of predicted 60  12
_VCO2 peak, ml min
-1 961  350
RER peak 0.97  0.09
_VE peak, L min1 37  8
_VE peak/MVV 0.71  0.12
VT peak, L 1.12  0.18
f peak, rpm 34  6
SpO2 peak, % 89  4
HR peak, % predicted 88  10
Borg dyspnea scores 7 (4e9)
Borg leg effort scores 6 (1e10)
Values are means  standard deviation, except for symptoms
(median and range).
Definition of abbreviations: FEV1Z forced expiratory volume in
1 s; FVC Z forced vital capacity; IC Z inspiratory capacity;
TLCZ total lung capacity; RVZ residual volume; DLCOZ lung
diffusing capacity for carbon monoxide; Pa Z arterial partial
pressure; Sa Z arterial saturation. _VO2 Z oxygen uptake;
_VCO2 Z carbon dioxide output; RER Z ratio exchange ratio;
_VEZminute ventilation; MVVZmaximal voluntary ventilation;
VT Z tidal volume; f Z respiratory frequency;
SpO2 Z oxyhemoglobin saturation by pulse oximetry;
HR Z heart rate.Both interventions resulted in improvement in FEV1, FVC, IC
and EELV, but FOR-TIO led to greater changes in FEV1, IC
and EELV than FOR-PLA.
Inspiratory muscle strength
Fig. 2 shows PImax evaluated at rest, at the end of CWT,
and at 2, 5, and 10 min during recovery. FOR þ TIO
improved PImax at rest, immediately after exercise and
during recovery, while FOR þ PLA improved PImax only at
10 min during recovery. Overall, FOR þ TIO resulted in
significantly larger increments in PImax at all points of
comparison.
Constant work exercise test
After 2 weeks of intervention, Tlim during CWT was
increased by FOR þ PLA (501  178 s to 702  145 s;
p < 0.05) and by FOR þ TIO (488  150 s vs. 899  123;
p < 0.05), but the size of the increment was significantly
larger with FOR þ TIO (40.7  7.6% vs. 84.5  8.2%;
p < 0.05). As shown in Table 3, at Tlim, _VO2, _VCO2, _VE, and
VT were increased only by FOR þ TIO, while respiratory
exchange ratio, breathing frequency, heart rate, and scores
for dyspnea and leg effort were unchanged by either
intervention. _VE=MVV, VT, EELV, and IC were improved by
both interventions, but FOR þ TIO resulted in a significantly
larger effect.
Pulmonary _VO2 kinetics after constant work exercise was
improved only with FOR þ TIO. Fig. 3 depicts the responses
of a representative patient, and Table 4 shows that the
amplitude increased while the time constant and the time
delay of recovery _VO2 kinetics decreased with FOR þ TIO.
Considering all patients in the analyses, at baseline,
PImax was significantly correlated to Tlim (0.51, p < 0.01)
and to tO2off (0.65, p < 0.01). Likewise, baseline t _VO2off
was significantly correlated to Tlim (0.77, p < 0.001). The
change in PImax after intervention correlated with the
change in Tlim (0.78, p < 0.001) and with the change in
t _VO2off (0.83, p < 0.001). Finally, the change in t _VO2off
with intervention was significantly correlated with the
change in Tlim (0.91, p < 0.001).
Discussion
In this randomized, crossover trial, we have shown that the
addition of TIO to FOR improved inspiratory strength at rest
and after exercise and accelerated recovery oxygen in
patients with COPD. Moreover, in a different group of
patients, we confirmed the findings of our previous trial,1
by showing that the addition of TIO to FOR improved
exercise performance and effort-induced dynamic hyper-
inflation. To our knowledge, this is the first evidence that
the addition of TIO to FOR improves respiratory muscle
performance and recovery from exhaustive exercise in this
patient population.
Weiner et al13 found no improvement in inspiratory
muscle strength and endurance after 6 weeks of treatment
of salmeterol in patients with COPD. In agreement with
those results, our patients also showed no improvement in
inspiratory strength after 2 weeks of FOR, but the addition
Table 2 Pulmonary function before and after 2 weeks of treatment.
Formoterol þ placebo Formoterol þ tiotropium
Before After 2 weeks Before After 2 weeks
Trough Peak Trough Peak
FEV1, L 1.09  0.21 1.11  0.22 1.21  0.29a,b 1.07  0.25 1.11  0.12 1.25  0.32a,b,c
FEV1, % pred 40  11 41  9 45  14a,b 40  11 42  10 46  12a,b
FVC, L 2.55  0.66 2.56  0.48 2.66  0.98a,b 2.51  0.57 2.60  0.45 2.75  0.91a,b
FVC, % pred 69  10 70  12 74  11a,b 67  13 73  11 77  12a,b
FEV1/FVC, % 40  8 42  10 43  15 41  7 42  11 44  10
IC, L 1.66  0.45 1.78  0.88 2.02  0.49a,b 1.68  0.41 1.75  0.43 2.16  0.77a,b,c
IC, % pred 61  45 65  15 73  13a,b 62  33 67  18 78  13a,b,c
EELV, L 4.35  0.77 4.24  0.81 3.98  0.67a,b 4.34  0.59 4.28  0.83 3.85  0.77a,b,c
Values are means  SD. Definition of abbreviations: FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity;
IC Z inspiratory capacity; EELV Z end-expiratory lung volume.
a p < 0.05 from before within a given treatment.
b p < 0.05 from trough within a given treatment.
c p < 0.05 between-treatment comparison.
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tude to that obtained by Weiner et al12 with inspiratory
muscle training in their patients. Inspiratory muscle
training may improve PImax by several mechanisms,
including diaphragm hypertrophy,29 metabolic,30 and
neuromuscular adaptations.31 Previous studies have
demonstrated that b2-agonists may increase the maximal
force generated by the diaphragm32,33 by affecting its
length and geometry,34 which is mostly determined by lung
volume.33 Furthermore, there is evidence that b2-agonists
increase fat and carbohydrate oxidation, resulting in stim-
ulation of hepatic glucose production.35,36 Despite these
potential mechanisms for improvement in inspiratory
muscle strength, we found that FOR administration had no
significant effect on resting or post-exercise PImax (Fig. 2,
left panel).
In contrast, the addition of TIO resulted in a larger
increment in FEV1 and inspiratory capacity (Table 2), as
well as a significant improvement in resting PImax (Fig. 2).
O’Donnell et al37 compared the effects of TIO to placeboFigure 2 Maximal inspiratory pressure (PImax) at rest, immedi
recovery before (open circles) and after (closed circles) intervention
plus tiotropium (right panel). *P < 0.05 from baseline; yP < 0.05 badministered for 7e10 days in 11 patients with COPD. In
contrast to our findings, they failed to demonstrate
improvement in maximal inspiratory sniff pressure, which
corrects for changes in operating volumes. Our trial
included a much larger number of patients (38) and inter-
vention was used for two weeks, therefore with a larger
power to detect changes. Moreover, patients in both groups
received FOR, reducing even more the possibility of
a placebo effect.
The mechanisms by which the addition of TIO might
improve PImax at rest are not readily apparent from our data
and we can only speculate on possible explanations. Since
static maximal inspiratory pressure measured at the mouth
does not correct for operating volumes, it is conceivable
that changes in inspiratory volumes might have improved
the length and geometry of the diaphragm, resulting in
increased force as measured by PImax. This is partially
supported by the finding of a small but significant larger
improvement in EELV (Table 2) with the addition of TIO
during the evaluation at rest.ately constant work exercise, and at 2, 5 and 10 min during
for the formoterol plus placebo (left panel) and for formoterol
etween-treatment comparison.
Table 3 Measurements at the time to the limit of tolerance in the constant work tests before and after 2 weeks of
intervention.
Formoterol þ placebo Formoterol þ tiotropium
Before 2 weeks Before 2 weeks
Metabolic
_VO2, ml min
1 1058  302 1081  280 1010  260 1131  294a
_VCO2, ml min
1 1004  299 972  272 947  275.0 1021  306.9
RER 0.94  0.08 0.89  0.06 0.93  0.08 0.92  0.06
Ventilatory
_VE, L min
1 33.5  11.7 34.4  11.3 32.7  11.2 36.5  12.3b
_VE=MVV 0.81  0.18 0.76  0.13a 0.85  0.19 0.73  0.14a,b
VT, L 1.09  0.3 1.16  0.3a 1.04  0.3 1.24  0.3a,b
f, rpm 30  8 30  7 31  8 30  9
IC, L 1.41  0.4 1.56  0.4a 1.41  0.4 1.60  0.3a,b
EELV, L 3.85  0.67 3.71  0.54 3.91  0.75 3.45  0.51a,b
SpO2, % 85  6 86  6a 86  6 88  6a
Cardiac
HR, bpm 127  16 130  20 129  20 128  19
HR, % pred 82  10 83  12 83  12 82  11
Subjective
Borg dyspnoea scores 7 (3e10) 9 (1e10) 9 (3e10) 9 (1e10)
Borg leg effort scores 5 (0e10) 3.5 (0e10) 5 (0e10) 5.5 (0e10)
Values are means  SD except for symptoms (median and ranges). Definition of abbreviations: _VO2 Z oxygen uptake; _VCO2 Z carbon
dioxide output; RER Z respiratory exchange rate; VE Z minute ventilation; MVV Z maximal voluntary ventilation; VT Z tidal volume;
f Z respiratory rate; IC Z inspiratory capacity; HR Z heart rate; SpO2 Z oxyhemoglobin saturation by pulse oximetry.
a p < 0.05 from baseline.
b p < 0.05 between-treatment comparison.
Tiotropium improves inspiratory muscle strength in COPD 1409The measurement of PImax after exercise has been
previously evaluated by randomized studies as a reliable
indicator of inspiratory muscle fatigue.17 Previous studies
have reported that exhaustive exercise may lead to
a decline in PImax immediately after exercise in healthy
subjects.38 This also happens to patients with chronic
heart failure,6 especially those with inspiratory muscle
weakness.18 In some COPD patients, inspiratory muscle
function may be impaired, mainly due to dynamic hyper-
inflation.39,40 This may cause shortening of the diaphragm,Figure 3 Pulmonary _VO2 kinetics (off-transient) after constant wo
shows _VO2 kinetics before (continuous line) and after 2 weeks (dash
_VO2 kinetics before (continuous line) and after 2 weeks (dashed lin
transient [smaller time constant (t) of primary component].changing length-tension properties and decreasing PImax.
Dynamic hyperinflation may also evoke reduction in
inspiratory muscle strength by the abolition of the zone of
apposition of the costal portion of the diaphragm with the
rib cage, resulting in less lateral expansion of the thoracic
cage during inspiration and inward recoil of the chest wall,
which means that inspiratory muscles work not only
against the lung elastic recoil but also against the elastic
recoil of the chest wall.41 Exercise induces an increase in
diaphragm work, which has to overcome the increaserk rate exercise in a representative patient with COPD. Panel A
ed line) of formoterol plus placebo. Panel B shows interpolated
e) of formoterol plus tiotroprium. Note the faster kinetics off-
Table 4 Recovery measurements after constant work exercise before and after 2 weeks of intervention.
Variable Formoterol þ placebo Formoterol þ tiotropium
Before 2 weeks Before 2 weeks
Off-transient
_VO2ðoffÞ 1058  302 1081  280 1010  260 1131  294a,b,c
A 710  105 698  88 678  125 801  123a,b,c
t 72.1  18.7 66.1  15.3 68.9  21.1 60.4  17.8a,b,c
TD 16.5  5.2 17.2  4.5 18.8  7.4 14.2  5.6a
MRT 88  6.8 81  9.7 86  5.7 71  8.1a,b,c
Values are means  SD. Definition of abbreviations: _VO2ðoffÞ Z oxygen uptake at the end of exercise (mL min1); A Z amplitude;
t Z time constant; TD Z time delay; MRT Z Mean response time (t þ TD).
a p < 0.05 from basal within a given treatment.
b p < 0.05 post vs. pre within a given treatment.
c p < 0.05 between-treatment comparison.
1410 N.D. Canto et al.elastic load and intrinsic positive end-expiratory pressure,
by generating an abnormally higher proportion of PImax in
terms of pleural pressure swings for a given tidal volume
(called “ventilatory effort”).42 This may affect the pattern
of breathing, causing dyspnea and higher dynamic hyper-
inflation, and potentially induces respiratory muscle
fatigue.31 This response may be associated with increased
end-expiratory lung volume (EELV) and reduction in exer-
cise tolerance (inspiratory capacity to total lung capacity
ratio, IC/TLC  0.28).43 In our study, we showed a reduc-
tion in PImax immediately after CWT in both treatments,
which may reflect high-frequency fatigue of the respira-
tory muscles. The correlation between the change in
PImax after intervention and the improvement in Tlim
(r Z 0.72) suggests that in the change inspiratory muscle
strength after TIO administration is a major determinant
to the improvement in exercise performance in patients
with COPD.
In healthy subjects, the time required for the return of
PImax to pre-exercise values is 2 min38 In previous reports,
we and others have demonstrated that the time of recovery
is prolonged in chronic heart failure patients with inspira-
tory muscle weakness.18,38 In the present study, it was
observed that FOR þ TIO therapy reduced the recovery
time of inspiratory muscle strength, which is suggestive
with delayed development in diaphragmatic fatigue.38 This
effect was present despite a longer exercise duration,
higher metabolic rate and smaller ventilatory effort. It is
important to remember that recovery of muscle energy
stores depends on intrinsic histologic44 and biochemical
muscle alterations, impaired O2 delivery to skeletal
muscles and vascular dysfunction.22,45 Accordingly, we have
demonstrated that patients with moderate to severe COPD
have impaired central and peripheral cardiovascular
responses to exercise that lead to slower kinetics of cardiac
output and faster muscle deoxygenation profile following
the onset of heavy-intensity exercise.22 In a previous study,
we showed that the administration of inhaled short-acting
bronchodilators reduces lung hyperinflation and the
amplitude of muscle deoxygenation during high-intensity
cycling exercise in patients with moderate to severe
COPD, which are linked with faster on-exercise kinetics of
cardiac output.17 The importance of the inspiratory
muscles in _VO2 kinetics after exercise is underscored by thehigh correlation between the change in PImax and the
improvement in t _VO2off (r Z 0.83) after intervention in
our patients.
The potential limitation of our study lies in crossover
design and small number of patients. Therefore further
larger clinical trials with parallel design should be con-
ducted to evaluate the effects of the addition of TIO to
FOR on functional capacity and quality of life in patients
with COPD. However, special care was taken to allow for
an appropriate washout period between interventions,
reducing the possibility of a carry-over effect. Moreover,
we were able the reproduce the results or our previous
trial1 in a different group of COPD patients, underscoring
the consistency of our findings. Since the improvement of
inspiratory muscle strength by the addition of TIO is in
disagreement with the results of the smaller trial by
O’Donnel et al,37 this particular subject should further
evaluated, including studies to address the mechanism by
which TIO may improve inspiratory muscle strength in
COPD. In our study, we measured PImax for assessment
inspiratory muscle strength, while O’Donnel et al,37
measured maximal inspiratory sniff esophageal pressure.
Despite the known limitations of using a volitional test
such as PImax46 as a measure of inspiratory muscle
strength after exercise, the randomized, crossover design
of the present study strongly indicates that TIO adminis-
tration resulted in improvement in inspiratory muscle
strength.
Our results may have clinical implications. Previous
studies have demonstrated success in enhancing exercise
tolerance with TIO in COPD patients.1,46,47 The results of
the present and as well as our previous trial1 underscore the
usefulness of adding TIO to FOR to improve exercise
performance in this patient population. Moreover, the
improvement in oxygen uptake kinetics during recovery
may impact on capacity of patients to perform intermittent
exercise, which is used in daily activities. However, future
large clinical trials should be conducted to test the
hypothesis that this combined intervention may impact on
clinical outcomes.
In conclusion, the addition of TIO to FOR improves pre-
and post-exercise inspiratory muscle strength and acceler-
ates recovery oxygen uptake kinetics in patients with
COPD. These physiological effects may partially explain the
Tiotropium improves inspiratory muscle strength in COPD 1411improvement in exercise performance induced by the
addition of TIO to FOR.
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